CJC-1295 w/DAC

CJC-1295 w/DAC — Long-Acting GHRH Analog

CJC-1295 with DAC (Drug Affinity Complex) is a synthetic tetrasubstituted analog of growth hormone-releasing hormone (GHRH 1-29) engineered for extended biological activity. The DAC modification — a maleimidopropionic acid linker conjugated to D-Ala at position 2 — enables covalent binding to serum albumin, extending the peptide’s functional half-life from minutes to approximately 6-8 days in preclinical models.

Mechanism of Action

CJC-1295 binds to GHRH receptors on anterior pituitary somatotrophs, activating the Gs/adenylyl cyclase/cAMP signaling cascade to stimulate GH gene transcription and secretion. The DAC modification creates a sustained-release profile: after administration, the reactive maleimido group forms a covalent bond with albumin’s Cys-34 residue, creating a circulating depot that provides continuous receptor stimulation over days rather than hours.

Research Applications

• Sustained GH secretion and pulsatility studies
• Pharmacokinetic modeling of albumin-conjugated peptides
• IGF-1 axis stimulation and downstream signaling
• Comparative studies with non-DAC GHRH analogs
• Somatotropic axis modulation in aging models

Product Specifications

• Quantity: 5mg per vial
• Purity: ≥98% (HPLC verified)
• Form: Lyophilized powder
• Storage: Refrigerate after reconstitution
• Testing: USA lab tested, COA available

For research purposes only. Not for human use or consumption.